Pain Management Therapeutics Market

Pain Management Therapeutics Market (Therapeutics: Anticonvulsants, Antidepressants, Anesthetics, Non-steroidal Anti-inflammatory Drugs (NSAIDS), Opioids, Antimigraine Agents, and Other Non-narcotic Analgesics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Pain Management Therapeutics Market Outlook 2031

  • The global pain management therapeutics market was valued at US$ 73.6 Bn in 2021
  • The global market is projected to grow at a CAGR of 2.9% from 2022 to 2031
  • The global pain management therapeutics market is anticipated to reach more than US$ 98.0 Bn by the end of 2031

Analysts’ Viewpoint on Pain Management Therapeutics Market Scenario

Personalization of pain therapies has been led by genetic evaluation tests based on analyzing patient’s deoxyribonucleic acid (DNA) to find appropriate medication for efficient pain management and avoid medicines that could cause severe side-effects. Availability of personalized pain therapies providing more accurate, efficient, and cost-efficient treatment is expected to present significant opportunities for pain management therapeutics market players in the near future. Moreover, several alternative medications with extended release are in development phase for the treatment of chronic and post-operative pain management. Approval of efficient alternative medicines for mild to chronic pain is expected to drive the global pain management therapeutics market size during the forecast period. Furthermore, a broad array of drugs has been developed for the treatment of multiple pain and inflammatory conditions driven by continuous improvement in the biopharmaceutical properties of available drugs.

Pain Management Therapeutics Market

Pain Management Therapeutics Market Introduction

Treatments for chronic pain are as different as the causes. Milder forms of pain could be relieved by over-the-counter medications such as Tylenol (acetaminophen) or nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen, and naproxen. Both acetaminophen and NSAIDs relieve pain caused by muscle aches and stiffness, and additionally, NSAIDs reduce inflammation (swelling and irritation). Topical pain relievers are also available, such as creams, lotions, or sprays, which are applied to the skin in order to relieve pain and inflammation from sore muscles and arthritis.

Request a sample to get extensive insights into the Pain Management Therapeutics Market

Increase in Incidence of Chronic Pain Disorders to Promote Usage of Pain Management Therapeutics

The number of patients suffering from chronic pain is rising constantly across the globe. According to the Centers for Disease Control and Prevention (CDC), in 2019, 20.4% of adults in the U.S. had chronic pain and 7.4% of adults had chronic pain that frequently limited life or work activities. According to the European Pain Federation, around 80 million adults in Europe suffer from chronic pain. Increase in incidence rate of cancer across the world contributes to a rise in the demand for pain management therapeutics. This includes pain occurring from cancer therapy as well as from incursion of cancer cells on to bones and other healthy body parts. WHO projections suggest that the global cancer prevalence would increase by around 75% from 2008 to 2030. Therefore, surge in incidence of chronic pain continues to encourage the usage of pain management drugs, which in turn is driving the global market.

Easy and Effective Medications Propel Consumption and Acceptance of Pain Management Drugs

Doctors usually prescribe medicines in the initial stages of pain, followed by other treatment options. Prescription drugs are easy and cost-effective without any ambiguity. Moreover, high cost of other alternate pain relief methods such as chiropractics, acupuncture, and acupressure have further driven the prescription drugs market, as cost of one session could equal the cost of complete therapeutic pain relief course for a patient through drugs. Increase in awareness about the availability of medications for pain management propels the consumption and acceptance of pain management drugs over other treatment options. Therefore, high availability, easy access, high awareness, cost effectiveness, and quick relief have made pain management therapeutics more preferable to other treatment options.

Request a custom report on Pain Management Therapeutics Market

Surge in Prescription Medications to Treat Chronic Pain Fueling Opioids Segment

In terms of therapeutic, the opioids segment dominated the global market in 2021. Opioids are the most widely prescribed pain management medications to treat moderate to severe chronic pain. Analgesics care in the form of analgesics is provided to cancer patients and treat severe constant pain in patients suffering from terminal illnesses. These are generally administered via subcutaneous, oral, or intramuscular route. Other routes of administration include nasal insufflation, patient-controlled analgesia, and transdermal and oral mucosa routes via lozenges. Opioids can be segmented into three major classes: strong agonists (fentanyl, oxymorphone, and morphine), mild-to-moderate agonists (codeine and hydroxycodone), and opioids with mixed receptor reactions (buprenophrine and pentazocine). The opioids segment has been segregated into oxycodones, hydrocodones, tramadol, and others. The hydrocodones sub-segment led the opioids segment in 2021 due to the introduction and adoption of abuse-deterrent formulations (ADFs).

On the other hand, the NSAIDs (non-steroidal anti-inflammatory drugs) segment is expected to gain pain management therapeutics market share during the forecast period owing to increase in the adoption of NSAIDs to manage mild to moderate pain with proven efficacy and fewer side-effects in the last few decades. Unlike opioids, NSAIDs are not associated with tolerance and dependence, hence the preference for NSAIDs is increasing over other pain management therapeutics.

Rise in Prevalence of Cancer is Propelling Cancer Pain Segment

Based on indication, the cancer pain segment accounted for the largest share of the global pain management therapeutics market in 2021 owing to increasing cases of cancer across the world. Globally, rise in prevalence of cancer is propelling the demand for pain therapeutics in the management of cancer pain. According to International Association of Study of Pain, for the more than 10 million people worldwide who are diagnosed with some form of cancer each year, pain associated with their condition is a serious concern. According to International Agency for Research on Cancer (IARC) estimates, 17.0 million new cancer cases and 9.5 million cancer deaths were reported globally in 2018. By 2040, the global burden is expected to rise to 27.5 million new cancer cases and 16.3 million cancer deaths due to increase in the geriatric population.

As per pain management therapeutics market forecast, the chronic back pain segment is likely to gain market share during the forecast period due to rise in prevalence of chronic low back pain. Nearly 65 million people in the U.S. report an episode of back pain. Some 16 million adults (8%) experience persistent or chronic back pain, and as a result are limited in certain everyday activities. Lower back pain affects an estimated 540 million people across the globe. More than one in ten suffer from lower back pain.

Regional Analysis of Global Pain Management Therapeutics Market

North America is expected to account for the largest share of the global pain management therapeutics market during the forecast period. This is ascribed to improved healthcare policies, changes in lifestyle, advancement in healthcare facilities, and availability of effective and convenient treatment options in the U.S. and Canada.

The market in Asia Pacific is likely to grow at a rapid pace in the next few years. Developing countries in the region such as Japan, China, and India are expected to contribute to the rise in demand for therapeutic pain management therapeutics, increase in awareness, and early availability of pain management therapeutic products.

Analysis of Key Players in Global Pain Management Therapeutics Market

The pain management therapeutics market report concludes with the company profiles section that includes key information about major players in the market. Key players are focusing on product launches, mergers & acquisitions, partnerships, and collaborations to enhance their pain management therapeutics market share. Abbott, AstraZeneca plc, Pfizer, Inc., Depomed, Inc. Endo International plc, GlaxoSmithKline plc, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Novartis AG, Purdue Pharma L.P., Teva Pharmaceutical Industries Ltd., Venus Remedies Limited, and Q Biomed, Inc. are the prominent players operating in the global market.

Key Developments in Global Pain Management Therapeutics Market

  • In July 2021, Venus Remedies Limited launched a distinct consumer healthcare subsidiary to supply advanced pain diagnostics & solutions
  • In March 2020, Pfizer, Inc. and Eli Lilly and Company received USFDA approval for Tanezumab 2.5 mg, administered subcutaneously (SC) in the treatment of chronic pain due to moderate-to-severe osteoarthritis (OA)
  • In November 2019, Q Biomed, Inc. received FDA approval to manufacture Strontium-89 Chloride USP, which helps in the treatment of skeletal metastases caused due to cancer

Each of these players has been profiled in the pain management therapeutics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Pain Management Therapeutics Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 73.6 Bn

Market Forecast Value in 2031

More than US$ 98.0 Bn

Compound Annual Growth Rate (CAGR)

2.9%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Therapeutics
    • Anticonvulsants
    • Antidepressants
    • Anesthetics
    • NSAIDs
    • Opioids
      • Oxycodones
      • Hydrocodones
      • Tramadol
      • Others
    • Antimigraine Agents
    • Other Non-narcotic Analgesics
  • Indication
    • Neuropathic Pain
    • Fibromyalgia
    • Arthritic Pain
    • Chronic Back Pain
    • Migraine
    • Post-operative Pain
    • Cancer Pain
  • Route of Administration
    • Oral
    • Parenteral
    • Others
  • Distribution Channel
    • Retail Pharmacies
    • Online Pharmacies
    • Others

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Abbott
  • AstraZeneca plc
  • Pfizer, Inc.
  • Depomed, Inc.
  • Endo International plc
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Mallinckrodt Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG
  • Purdue Pharma L.P.
  • Teva Pharmaceutical Industries Ltd.
  • Venus Remedies Limited
  • Q Biomed Inc.

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global pain management therapeutics market in 2021?

The global pain management therapeutics market was valued at US$ 73.6 Bn in 2021.

How big will be the global pain management therapeutics market in 2031?

The global market is projected to reach more than US$ 98.0 Bn by 2031.

What will be the CAGR of the global pain management therapeutics market during the forecast period (2022–2031)?

The global pain management therapeutics market is anticipated to grow at a CAGR of 2.9% from 2022 to 2031.

Which are the prominent trends that affect market growth?

Increase in incidence of chronic pain disorders is driving the global market.

Who are the prominent players in the global pain management therapeutics market?

Abbott, AstraZeneca plc, Pfizer, Inc., Depomed, Inc. Endo International plc, GlaxoSmithKline plc, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Novartis AG, Purdue Pharma L.P., Teva Pharmaceutical Industries Ltd., Venus Remedies Limited, and Q Biomed, Inc. are the prominent players oerating in the global market.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Pain Management Therapeutics Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Therapeutics Definition

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Pain Management Therapeutics Market Analysis and Forecast, 2017–2031

            4.4.1. Market Revenue Projections (US$ Mn)

        4.5. Porter’s Five Force Analysis

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Key Mergers & Acquisitions

        5.3. Covid 19 Impact Analysis

    6. Global Pain Management Therapeutics Market Analysis and Forecast, by Therapeutic

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Therapeutic, 2017–2031

            6.3.1. Anticonvulsants

            6.3.2. Antidepressants

            6.3.3. Anesthetics

            6.3.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

            6.3.5. Opioids

            6.3.6. Other Non-narcotic Analgesic

            6.3.7. Antimigraine Agents

        6.4. Market Attractiveness Analysis, by Therapeutic

    7. Global Pain Management Therapeutics Market Analysis and Forecast, by Indication

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Indication, 2017–2031

            7.3.1. Neuropathic Pain

            7.3.2. Fibromyalgia

            7.3.3. Arthritic Pain

            7.3.4. Chronic Back Pain

            7.3.5. Migraine

            7.3.6. Post-operative Pain

            7.3.7. Cancer Pain

        7.4. Market Attractiveness Analysis, by Indication

    8. Global Pain Management Therapeutics Market Analysis and Forecast, by Route of Administration

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Route of Administration, 2017–2031

            8.3.1. Oral

            8.3.2. Parenteral

            8.3.3. Others

        8.4. Market Attractiveness Analysis, by Route of Administration

    9. Global Pain Management Therapeutics Market Analysis and Forecast, by Distribution Channel

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Market Value Forecast, by Distribution Channel, 2017–2031

            9.3.1. Retail Pharmacies

            9.3.2. Online Pharmacies

            9.3.3. Others

        9.4. Market Attractiveness Analysis, by Distribution Channel

    10. Global Pain Management Therapeutics Market Analysis and Forecast, by Region

        10.1. Key Findings

        10.2. Market Value Forecast, by Region

            10.2.1. North America

            10.2.2. Europe

            10.2.3. Asia Pacific

            10.2.4. Latin America

            10.2.5. Middle East & Africa

        10.3. Market Attractiveness Analysis, by Region

    11. North America Pain Management Therapeutics Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Therapeutic, 2017–2031

            11.2.1. Anticonvulsants

            11.2.2. Antidepressants

            11.2.3. Anesthetics

            11.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

            11.2.5. Opioids

            11.2.6. Other Non-narcotic Analgesic

            11.2.7. Antimigraine Agents

        11.3. Market Value Forecast, by Indication, 2017–2031

            11.3.1. Neuropathic Pain

            11.3.2. Fibromyalgia

            11.3.3. Arthritic Pain

            11.3.4. Chronic Back Pain

            11.3.5. Migraine

            11.3.6. Post-operative Pain

            11.3.7. Cancer Pain

        11.4. Market Value Forecast, by Route of Administration, 2017–2031

            11.4.1. Oral

            11.4.2. Parenteral

            11.4.3. Others

        11.5. Market Value Forecast, by Distribution Channel, 2017–2031

            11.5.1. Retail Pharmacies

            11.5.2. Online Pharmacies

            11.5.3. Others

        11.6. Market Value Forecast, by Country, 2017–2031

            11.6.1. U.S.

            11.6.2. Canada

        11.7. Market Attractiveness Analysis

            11.7.1. By Therapeutic

            11.7.2. By Indication

            11.7.3. By Route of Administration

            11.7.4. By Distribution Channel

            11.7.5. By Country

    12. Europe Pain Management Therapeutics Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Therapeutic, 2017–2031

            12.2.1. Anticonvulsants

            12.2.2. Antidepressants

            12.2.3. Anesthetics

            12.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

            12.2.5. Opioids

            12.2.6. Other Non-narcotic Analgesic

            12.2.7. Antimigraine Agents

        12.3. Market Value Forecast, by Indication, 2017–2031

            12.3.1. Neuropathic Pain

            12.3.2. Fibromyalgia

            12.3.3. Arthritic Pain

            12.3.4. Chronic Back Pain

            12.3.5. Migraine

            12.3.6. Post-operative Pain

            12.3.7. Cancer Pain

        12.4. Market Value Forecast, by Route of Administration, 2017–2031

            12.4.1. Oral

            12.4.2. Parenteral

            12.4.3. Others

        12.5. Market Value Forecast, by Distribution Channel, 2017–2031

            12.5.1. Retail Pharmacies

            12.5.2. Online Pharmacies

            12.5.3. Others

        12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.6.1. Germany

            12.6.2. U.K.

            12.6.3. France

            12.6.4. Spain

            12.6.5. Italy

            12.6.6. Rest of Europe

        12.7. Market Attractiveness Analysis

            12.7.1. By Therapeutic

            12.7.2. By Indication

            12.7.3. By Route of Administration

            12.7.4. By Distribution Channel

            12.7.5. By Country/Sub-region

    13. Asia Pacific Pain Management Therapeutics Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Therapeutic, 2017–2031

            13.2.1. Anticonvulsants

            13.2.2. Antidepressants

            13.2.3. Anesthetics

            13.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

            13.2.5. Opioids

            13.2.6. Other Non-narcotic Analgesic

            13.2.7. Antimigraine Agents

        13.3. Market Value Forecast, by Indication, 2017–2031

            13.3.1. Neuropathic Pain

            13.3.2. Fibromyalgia

            13.3.3. Arthritic Pain

            13.3.4. Chronic Back Pain

            13.3.5. Migraine

            13.3.6. Post-operative Pain

            13.3.7. Cancer Pain

        13.4. Market Value Forecast, by Route of Administration, 2017–2031

            13.4.1. Oral

            13.4.2. Parenteral

            13.4.3. Others

        13.5. Market Value Forecast, by Distribution Channel, 2017–2031

            13.5.1. Retail Pharmacies

            13.5.2. Online Pharmacies

            13.5.3. Others

        13.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.6.1. China

            13.6.2. Japan

            13.6.3. India

            13.6.4. Australia & New Zealand

            13.6.5. Rest of Asia Pacific

        13.7. Market Attractiveness Analysis

            13.7.1. By Therapeutic

            13.7.2. By Indication

            13.7.3. By Route of Administration

            13.7.4. By Distribution Channel

            13.7.5. By Country/Sub-region

    14. Latin America Pain Management Therapeutics Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Therapeutic, 2017–2031

            14.2.1. Anticonvulsants

            14.2.2. Antidepressants

            14.2.3. Anesthetics

            14.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

            14.2.5. Opioids

            14.2.6. Other Non-narcotic Analgesic

            14.2.7. Antimigraine Agents

        14.3. Market Value Forecast, by Indication, 2017–2031

            14.3.1. Neuropathic Pain

            14.3.2. Fibromyalgia

            14.3.3. Arthritic Pain

            14.3.4. Chronic Back Pain

            14.3.5. Migraine

            14.3.6. Post-operative Pain

            14.3.7. Cancer Pain

        14.4. Market Value Forecast, by Route of Administration, 2017–2031

            14.4.1. Oral

            14.4.2. Parenteral

            14.4.3. Others

        14.5. Market Value Forecast, by Distribution Channel, 2017–2031

            14.5.1. Retail Pharmacies

            14.5.2. Online Pharmacies

            14.5.3. Others

        14.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.6.1. Brazil

            14.6.2. Mexico

            14.6.3. Rest of Latin America

        14.7. Market Attractiveness Analysis

            14.7.1. By Therapeutic

            14.7.2. By Indication

            14.7.3. By Route of Administration

            14.7.4. By Distribution Channel

            14.7.5. By Country/Sub-region

    15. Middle East & Africa Pain Management Therapeutics Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast, by Therapeutic, 2017–2031

            15.2.1. Anticonvulsants

            15.2.2. Antidepressants

            15.2.3. Anesthetics

            15.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

            15.2.5. Opioids

            15.2.6. Other Non-narcotic Analgesic

            15.2.7. Antimigraine Agents

        15.3. Market Value Forecast, by Indication, 2017–2031

            15.3.1. Neuropathic Pain

            15.3.2. Fibromyalgia

            15.3.3. Arthritic Pain

            15.3.4. Chronic Back Pain

            15.3.5. Migraine

            15.3.6. Post-operative Pain

            15.3.7. Cancer Pain

        15.4. Market Value Forecast, by Route of Administration, 2017–2031

            15.4.1. Oral

            15.4.2. Parenteral

            15.4.3. Others

        15.5. Market Value Forecast, by Distribution Channel, 2017–2031

            15.5.1. Retail Pharmacies

            15.5.2. Online Pharmacies

            15.5.3. Others

        15.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            15.6.1. GCC Countries

            15.6.2. South Africa

            15.6.3. Rest of Middle East & Africa

        15.7. Market Attractiveness Analysis

            15.7.1. By Therapeutic

            15.7.2. By Indication

            15.7.3. By Route of Administration

            15.7.4. By Distribution Channel

            15.7.5. By Country/Sub-region

    16. Competition Landscape

        16.1. Market Player - Competition Matrix (by tier and size of companies)

        16.2. Market Share Analysis, by Company, 2021

        16.3. Company Profiles

            16.3.1. Abbott Laboratories

                16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.1.2. Financial Analysis

                16.3.1.3. Growth Strategies

                16.3.1.4. SWOT Analysis

            16.3.2. AstraZeneca plc

                16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.2.2. Financial Analysis

                16.3.2.3. Growth Strategies

                16.3.2.4. SWOT Analysis

            16.3.3. Pfizer, Inc.

                16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.3.2. Financial Analysis

                16.3.3.3. Growth Strategies

                16.3.3.4. SWOT Analysis

            16.3.4. Depomed, Inc.

                16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.4.2. Financial Analysis

                16.3.4.3. Growth Strategies

                16.3.4.4. SWOT Analysis

            16.3.5. Endo International plc

                16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.5.2. Financial Analysis

                16.3.5.3. Growth Strategies

                16.3.5.4. SWOT Analysis

            16.3.6. GlaxoSmithKline plc

                16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.6.2. Financial Analysis

                16.3.6.3. Growth Strategies

                16.3.6.4. SWOT Analysis

            16.3.7. Johnson & Johnson Services, Inc.

                16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.7.2. Financial Analysis

                16.3.7.3. Growth Strategies

                16.3.7.4. SWOT Analysis

            16.3.8. Mallinckrodt Pharmaceuticals

                16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.8.2. Financial Analysis

                16.3.8.3. Growth Strategies

                16.3.8.4. SWOT Analysis

            16.3.9. Merck & Co., Inc.

                16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.9.2. Financial Analysis

                16.3.9.3. Growth Strategies

                16.3.9.4. SWOT Analysis

            16.3.10. Novartis AG

                16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.10.2. Financial Analysis

                16.3.10.3. Growth Strategies

                16.3.10.4. SWOT Analysis

            16.3.11. Purdue Pharma L.P.

                16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.11.2. Financial Analysis

                16.3.11.3. Growth Strategies

                16.3.11.4. SWOT Analysis

            16.3.12. Teva Pharmaceutical Industries Ltd

                16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.12.2. Financial Analysis

                16.3.12.3. Growth Strategies

                16.3.12.4. SWOT Analysis

            16.3.13. Venus Remedies Limited

                16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.13.2. Financial Analysis

                16.3.13.3. Growth Strategies

                16.3.13.4. SWOT Analysis

            16.3.14. Q Biomed, Inc.

                16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.14.2. Financial Analysis

                16.3.14.3. Growth Strategies

                16.3.14.4. SWOT Analysis

    List of Tables

    Table 01: Global Pain Management Therapeutics Market Value Share, by Therapeutic, 2021

    Table 02: Global Pain Management Therapeutics Market Value Share, by Indication, 2021

    Table 03: Global Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Therapeutic, 2017–2031

    Table 04: Global Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 05: Global Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 06: Global Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 07: Global Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 08: North America Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Therapeutic, 2017–2031

    Table 09: North America Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 10: North America Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 11: North America Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 12: North America Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 13: Europe Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Therapeutic, 2017–2031

    Table 14: Europe Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 15: Europe Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 16: Europe Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 17: Europe Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 18: Asia Pacific Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Therapeutic, 2017–2031

    Table 19: Asia Pacific Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 20: Asia Pacific Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 21: Asia Pacific Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 22: Asia Pacific Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 23: Latin America Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Therapeutic, 2017–2031

    Table 24: Latin America Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 25: Latin America Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 26: Latin America Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 27: Latin America Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 28: Middle East & Africa Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Therapeutic, 2017–2031

    Table 29: Middle East & Africa Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 30: Middle East & Africa Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

    Table 31: Middle East & Africa Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 32: Middle East & Africa Pain Management Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    List of Figures

    Figure 01: Global Pain Management Therapeutics Market Snapshot

    Figure 02: Global Pain Management Therapeutics Market Segments With Leading Market Share (%), 2021

    Figure 03: Key Industry Developments (Pain Management Therapeutics Market)

    Figure 04: Global Pain Management Therapeutics Market Value (US$ Mn) Forecast, 2017‒2031

    Figure 05: Global Pain Management Therapeutics Market Value Share (%), by Therapeutic (2021)

    Figure 06: Global Pain Management Therapeutics Market Value Share (%), by Indication (2021)

    Figure 07: Global Pain Management Therapeutics Market Value Share (%), by Route of Administration (2021)

    Figure 08: Global Pain Management Therapeutics Market Value Share(%), by Distribution Channel (2021)

    Figure 09: Global Pain Management Therapeutics Market Value Share (%), by Region (2021)

    Figure 10: Global Pain Management Therapeutics Market Value Share Analysis, by Therapeutic, 2021 and 2031

    Figure 11: Global Pain Management Therapeutics Market Attractiveness Analysis, by Therapeutic, 2022–2031

    Figure 12: Global Pain Management Therapeutics Market Value Share Analysis, by Indication, 2021 and 2031

    Figure 13: Global Pain Management Therapeutics Market Attractiveness Analysis, by Indication, 2022–2031

    Figure 14: Global Pain Management Therapeutics Market Value Share Analysis, by Route of Administration, 2021 and 2031

    Figure 15: Global Pain Management Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

    Figure 16: Global Pain Management Therapeutics Market Value Share(%), by Distribution Channel, 2021 and 2031

    Figure 17: Global Pain Management Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 18: Global Pain Management Therapeutics Market Value Share Analysis, by Region 2021 and 2031

    Figure 19: Global Pain Management Therapeutics Market Attractiveness Analysis, by Region, 2022–2031

    Figure 20: North America Pain Management Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031

    Figure 21: North America Pain Management Therapeutics Market Value Share (%), by Therapeutic, 2021 and 2031

    Figure 22: North America Pain Management Therapeutics Market Attractiveness Analysis, by Therapeutic, 2022–2031

    Figure 23: North America Pain Management Therapeutics Market Value Share (%), by Indication, 2021 and 2031

    Figure 24: North America Pain Management Therapeutics Market Attractiveness Analysis, by Indication, 2022–2031

    Figure 25: North America Pain Management Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031

    Figure 26: North America Pain Management Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

    Figure 27: North America Pain Management Therapeutics Market Share (%), by Distribution Channel, 2021 and 2031

    Figure 28: North America Pain Management Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 29: North America Pain Management Therapeutics Market Value Share (%), by Country, 2021 and 2031

    Figure 30: North America Pain Management Therapeutics Market Attractiveness Analysis, by Country, 2022–2031

    Figure 31: Europe Pain Management Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031

    Figure 32: Europe Pain Management Therapeutics Market Value Share (%), by Therapeutic, 2021 and 2031

    Figure 33: Europe Pain Management Therapeutics Market Attractiveness Analysis, by Therapeutic, 2022–2031

    Figure 34: Europe Pain Management Therapeutics Market Value Share (%), by Indication, 2021 and 2031

    Figure 35: Europe Pain Management Therapeutics Market Attractiveness Analysis, by Indication, 2022–2031

    Figure 36: Europe Pain Management Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031

    Figure 37: Europe Pain Management Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

    Figure 38: Europe Pain Management Therapeutics Market Share (%), by Distribution Channel, 2021 and 2031

    Figure 39: Europe Pain Management Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 40: Europe Pain Management Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031

    Figure 41: Europe Pain Management Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 42: Asia Pacific Pain Management Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031

    Figure 43: Asia Pacific Pain Management Therapeutics Market Value Share (%), by Therapeutic, 2021 and 2031

    Figure 44: Asia Pacific Pain Management Therapeutics Market Attractiveness Analysis, by Therapeutic, 2022–2031

    Figure 45: Asia Pacific Pain Management Therapeutics Market Value Share (%), by Indication, 2021 and 2031

    Figure 46: Asia Pacific Pain Management Therapeutics Market Attractiveness Analysis, by Indication, 2022–2031

    Figure 47: Asia Pacific Pain Management Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031

    Figure 48: Asia Pacific Pain Management Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

    Figure 49: Asia Pacific Pain Management Therapeutics Market Share (%), by Distribution Channel, 2021 and 2031

    Figure 50: Asia Pacific Pain Management Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 51: Asia Pacific Pain Management Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031

    Figure 52: Asia Pacific Pain Management Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 53: Latin America Pain Management Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031

    Figure 54: Latin America Pain Management Therapeutics Market Value Share (%), by Therapeutic, 2021 and 2031

    Figure 55: Latin America Pain Management Therapeutics Market Attractiveness Analysis, by Therapeutic, 2022–2031

    Figure 56: Latin America Pain Management Therapeutics Market Value Share (%), by Indication, 2021 and 2031

    Figure 57: Latin America Pain Management Therapeutics Market Attractiveness Analysis, by Indication, 2022–2031

    Figure 58: Latin America Pain Management Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031

    Figure 59: Latin America Pain Management Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

    Figure 60: Latin America Pain Management Therapeutics Market Share (%), by Distribution Channel, 2021 and 2031

    Figure 61: Latin America Pain Management Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 62: Latin America Pain Management Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031

    Figure 63: Latin America Pain Management Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 64: Middle East & Africa Pain Management Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031

    Figure 65: Middle East & Africa Pain Management Therapeutics Market Value Share (%), by Therapeutic, 2021 and 2031

    Figure 66: Middle East & Africa Pain Management Therapeutics Market Attractiveness Analysis, by Therapeutic, 2022–2031

    Figure 67: Middle East & Africa Pain Management Therapeutics Market Value Share (%), by Indication, 2021 and 2031

    Figure 68: Middle East & Africa Pain Management Therapeutics Market Attractiveness Analysis, by Indication, 2022–2031

    Figure 69: Middle East & Africa Pain Management Therapeutics Market Value Share (%), by Route of Administration, 2021 and 2031

    Figure 70: Middle East & Africa Pain Management Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

    Figure 71: Middle East & Africa Pain Management Therapeutics Market Share (%), by Distribution Channel, 2021 and 2031

    Figure 72: Middle East & Africa Pain Management Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 73: Middle East & Africa Pain Management Therapeutics Market Value Share (%), by Country/Sub-region, 2021 and 2031

    Figure 74: Middle East & Africa Pain Management Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Copyright © Transparency Market Research, Inc. All Rights reserved